Notice of Termination of License Agreement between Arbutus Biopharma Inc. and Kuros Biosciences AG (formerly Cytos Biotechnology Ltd)

Contract Categories: Business Operations › Termination Agreements
Summary

Arbutus Biopharma Inc. and its parent company, Arbutus Pharma Corp., are formally notifying Kuros Biosciences AG (formerly Cytos Biotechnology Ltd) of the termination of their License Agreement, originally signed on December 30, 2014. The termination is made for convenience as allowed under the agreement. This letter serves as the official written notice required to end the agreement between the parties.

Read More Arrow
EX-10.65 5 exhibit1065_cytosterminati.htm EX 10.65 CYTOS TERMINATION Exhibit


Exhibit 10.65


August 25, 2016

Didier Cowling
Chief Executive Officer
Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland

Dear Mr. Cowling,

This letter constitutes written notice of termination by Arbutus Biopharma Inc., and its parent company Arbutus Pharma Corp. (collectively “Arbutus”) of the License Agreement by and between Cytos Biotechnology Ltd and Oncore Biopharma, Inc. (predecessor in interest of Arbutus), dated December 30, 2014 (“Agreement”), pursuant to § 12.3 (Termination of the Agreement for Convenience) of said Agreement.

Yours truly,
/s/ Elizabeth Howard
Elizabeth Howard
Executive Vice President & General Counsel

Cc:     VISCHER AG
Aeschenvorstadt 4
4010 Basel
Switzerland
Attn: Dr. Matthias Staehelin